ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2013
Lenalidomide for multiple myeloma: cost-effectiveness in patients with one prior therapy in England and Wales.
Article in The European journal of health economics : HEPAC : health economics in prevention and care, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Cost Effectiveness of Transplant, Conventional Chemotherapy, and Novel Agents in Multiple Myeloma: A Systematic Review.PharmacoEconomics · 2019Pooled it
- Methodology and results of real-world cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone in relapsed multiple myeloma using registry data.The European journal of health economics : HEPAC : health economics in prevention and care · 2020Trial
- Cost utility and budget impact analysis of dexamethasone compared with bortezomib and lenalidomide for the treatment of second line multiple myeloma from a South African public health perspective.Cost effectiveness and resource allocation : C/E · 2022Article
- The value of survival gains from therapeutic innovations for US patients with relapsed/refractory multiple myeloma.Therapeutic advances in hematology · 2021Article
- Is lenalidomide the standard-of-care after an autotransplant for plasma cell myeloma?Leukemia · 2019Review
- Temporal Trends in Survival and Healthcare Costs in Patients with Multiple Myeloma in the United States.American health & drug benefits · 2018Article
- Using pharmacy management systems for research: survival outcomes for lenalidomide in multiple myeloma in the clinical setting.International journal of clinical pharmacy · 2017Article
- Expression Profiles of the Individual Genes Corresponding to the Genes Generated by Cytotoxicity Experiments with Bortezomib in Multiple Myeloma.Turkish journal of haematology : official journal of Turkish Society of Haematology · 2016Article
- Quality-adjusted cost of care: a meaningful way to measure growth in innovation cost versus the value of health gains.Health affairs (Project Hope) · 2015Article
- Aloperine executes antitumor effects against multiple myeloma through dual apoptotic mechanisms.Journal of hematology & oncology · 2015Article
- Clinical utility and patient consideration in the use of lenalidomide for multiple myeloma in Chinese patients.OncoTargets and therapy · 2015Review
- Double Relapsed and/or Refractory Multiple Myeloma: Clinical Outcomes and Real World Healthcare Costs.PloS one · 2015Article
- Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma.Health and quality of life outcomes · 2014Article
- Article
- Economic evaluation of therapies for patients suffering from relapsed-refractory multiple myeloma in Greece.Cancer management and research · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo determine the cost effectiveness of lenalidomide plus dexamethasone (LEN/DEX) versus DEX alone in managing multiple myeloma (MM) patients who have failed one prior therapy. MATERIALS AND
methodsAn individual simulation model was designed to capture the costs and outcomes of LEN/DEX versus DEX therapy in relapsed refractory MM patients. MM009/010 efficacy data were adjusted for treatment cross-over and extrapolated to patient lifetime. Resource use for MM disease progression and adverse events were obtained from expert physicians and costed from the perspective of the National Health Service (England and UK) and included a patient access scheme for LEN. Utility values were obtained from published literature.
resultsThe simulation model estimated an incremental improvement in time to progression of 9.5 months, an additional 3.2 life-years, and 2.2 quality adjusted life years (QALY) for LEN/DEX compared to DEX alone. Including the costs of therapy with the patient access scheme, adverse events, and disease follow-up, the incremental cost effectiveness ratio was £30,153/QALY for LEN/DEX compared to DEX alone in MM patients who have failed one prior therapy.
conclusionLEN/DEX is a cost effective oncology therapy from the perspective of the NHS for MM patients with one prior treatment.
Indexed as
Identifiers
22572968What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.